Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca AB

AstraZeneca clinical programs — 46 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

AstraZeneca projects

46 ClinicalTrials.gov programs sponsored by AstraZeneca.

AstraZeneca has 46 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

46 programs

Clinical programs

  1. A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

    AstraZeneca AB

    Advanced solid tumours

    phase 1 other active

    1 trial

  2. A trial to learn how baxdrostat affects the heartbeat in healthy participants

    AstraZeneca AB

    Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension

    phase 1 other active

    1 trial

  3. AZD5462-D9090C00012

    AstraZeneca AB

    Chronic Heart Failure

    phase 1 other active

    1 trial

  4. AZD5492

    AstraZeneca AB

    B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  5. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  6. D0816C00025

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

  7. D1346C00015

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

    phase 1 small molecule active

    1 trial

  8. D3560C00817

    AstraZeneca AB

    Clinical trial healthy volunteer

    phase 1 other active

    1 trial

  9. D3615C00005

    AstraZeneca AB

    Healthy participants

    phase 1 other active

    1 trial

  10. D5084C00016

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  11. D533BC00003

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  12. D5985C00008

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  13. D5985C00009

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  14. D6830C00004

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

  15. D702EC00001

    AstraZeneca AB

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  16. D7260C00007

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  17. D740AC00001

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis

    phase 1 other active

    1 trial

  18. D7860C00004

    AstraZeneca AB

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  19. D7860C00005

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  20. D7930C00003

    AstraZeneca AB

    advanced liver fibrosis

    phase 1 other active

    1 trial

  21. D8210C00006

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

  22. D8330C00004

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  23. D8340C00001

    AstraZeneca AB

    PLN R14del Dilated Cardiomyopathy

    phase 1 other active

    1 trial

  24. D8530C00001

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  25. D8990C00001

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  26. D8991C00002

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  27. D907HC00001

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  28. D9090C00007

    AstraZeneca AB

    Moderate Renal Impairment, Heart Failure

    phase 1 other active

    1 trial

  29. D9090C00010

    AstraZeneca AB

    Impaired renal function

    phase 1 other active

    1 trial

  30. D9180C00006

    AstraZeneca AB

    Inflammation, Respiratory

    phase 1 other active

    1 trial

  31. D9180C00011

    AstraZeneca AB

    healthy volunteers

    phase 1 other active

    1 trial

  32. D926FC00001

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  33. D933IC00001

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  34. D9440C00003

    AstraZeneca AB

    Healthy Volunteers, Renal Impairment and End Stage Kidney Disease

    phase 1 other active

    1 trial

  35. D9441C00001

    AstraZeneca AB

    Chronic Kidney disease, Atherosclerotic Cardiovascular Disease

    phase 1 other active

    1 trial

  36. D9441C00004

    AstraZeneca AB

    Cardiorenal disease

    phase 1 other active

    1 trial

  37. D9470C00001

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  38. D9609C00001

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  39. D9640C00001

    AstraZeneca AB

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  40. D967JC00002

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  41. D967YC00001

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  42. D9690C00007

    AstraZeneca AB

    Crohn's disease

    phase 1 other active

    1 trial

  43. D9723C00002

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  44. D9961C00001

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies

    phase 1 other active

    1 trial

  45. LENVIMA hard capsules for Advanced Renal Cell Carcinoma

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  46. PRIMROSE D9970C00001

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AstraZeneca have?

46 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.